As identified in previously published articles, including those published in this issue, the
detection of early cognitive impairment among older adult populations is worthy of …

Background Preclinical prediction of Alzheimer disease (AD) is important and critical to
effective intervention. Plasma levels of amyloid-β (Aβ) peptides have been a principal focus …

CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are
increasingly being used to define and stage Alzheimer's disease. These biomarkers can be …

Abstract Background Proteins pathogenic in Alzheimer's disease (AD) were extracted from
neurally derived blood exosomes and quantified to develop biomarkers for the staging of …

Introduction Plasma amyloid beta (Aβ) 1‐42/Aβ1‐40 ratio, phosphorylated‐tau181 (p‐
tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood …

Background According to the latest revised National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders …

Previous studies of Aβ plasma as a biomarker for Alzheimer's disease (AD) obtained
conflicting results. We here included 715 subjects with baseline Aβ 1-40 and Aβ 1-42 …

Purpose of review: With the move toward development of disease modifying treatments,
there is a need for more specific diagnosis of early Alzheimer's disease (AD) and mild …

Plasma amyloid-β (Aβ) levels have been proposed as biomarkers of Alzheimer's disease
(AD), but studies have produced inconsistent results. We present a meta-analytic review of …

Levels of amyloid-β (Aβ) and tau peptides in brain have been associated with Alzheimer
disease (AD). The current study investigated the abilities of plasma Aβ42 and total-tau (t-tau) …